OBJ's technology uses magnetic fields (PEMF) to assist getting products across the protective outer barriers of skin, hair, teeth. Given the great research that has already posted on OBJ by 'the usual suspects' I hope to also contribute something useful by posting some info on the PEMF technology over the coming months.
"Results have showed that gold nanoparticle-treated human skin exposed to the PEMF fields had 200 times more gold nanoparticle positive pixels than the non-exposed skin. This study suggests that PEMF is responsible for the formation of transient pores through which the nanoparticles can move and that the pores must be larger than the 10 nm diameter of these rigid particles."(http://www.obj.com.au/wp-content/uploads/Epidermal-Pore-Formation-by-Magnetic-Fields.pdf)
This pore size is significant. Recently Surges identifed his next technology of interest is Nanotech. By way of size comparisons for compounds moving thru skin pores; Liposome's range from 50-800nm, Nanopowder <50nm, Nanocrystals 2-100nm.(http://www.nanopaprika.eu/profiles/blogs/nanotechnology-based-drug). So if OBJ were to be used to support nanotech delivery then the pore size differential will need to be addressed - if it hasn't already.
Having said that, OBJ technology has been applied to a di-peptide molecule revealing that .."Dermaportation-magnetic field technology increased the in vitro permeability coefficient of Ala-Trp across human epidermis from 7.7x 10-4 cm/h with passive diffusion to 1.94x10-2 cm/h with Dermaportation." Interestingly this research also demonstrated that "Following permeation across the epidermis, a degradation product was detected in the receptor solution with the amount increasing up to 6 h. Given the susceptibility of peptides to degradation in the skin it is essential that they are delivered rapidly across the skin in order to maximize the opportunity for delivery of the native peptide." (http://onlinelibrary.wiley.com/doi/10.1002/bip.21033/abstract)
Of some further significance around this size issue is the following info which shows that for bioavailability reasons many of the pharmaceuticals in the market are of relatively low molecular weight and therefore size.
"Optimizing compounds for high activity on a biological target almost often goes along with increased molecular weights. However, compounds with higher weights are less likely to be absorbed and therefore to ever reach the place of action. Thus, trying to keep molecular weights as low as possible should be the desire of every drug forger. More than 80 % of all traded drugs have a molecular weight below 450." (http://www.organic-chemistry.org/prog/peo/mw.html)
bluebush
OBJ Price at posting:
2.4¢ Sentiment: LT Buy Disclosure: Held
(20min delay)